EGFR and non-small cell lung carcinoma: Identification of epidermal growth factor receptor (EGFR) kinase domain activating mutations in NSCLC patients led to several retrospective studies to confirm the relationships between the EGFR mutational status and treatment response to kinase inhibitors such as erlotinib and gefitinib7, 8, 9, 10.